Literature DB >> 499999

Effect of metabolic control on urinary excretion and plasma levels of catecholamines in diabetics.

G Bolli, M G Cartechini, P Compagnucci, S Malvicini, P De Feo, F Santeusanio, G Angeletti, P Brunetti.   

Abstract

Urinary excretion and plasma levels of catecholamines were determined in 20 normal and 39 diabetic subjects to evaluate the sympathetic activity. Diabetic patients were divided into 4 groups according to the metabolic control. Sympathetic activity showed no differences between normal and subjects with chemical diabetes (group I, n = 5). In insulin-treated diabetics in good metabolic control (group II, n = 11) only urinary excretion of free norepinephrine was significantly higher than normals (p less than .05). In insulin-treated diabetics in poor metabolic control (group III, n = 16) urinary excretion and plasma levels of norepinephrine showed a marked increase over groups I and II (p less than .001). In insulin-treated diabetics with ketosis (group IV, n = 7) urinary excretion and plasma levels of both norepinephrine and epinephrine showed the highest values (p less than .001 and less than .1). Finally, in groups III and IV, after achieving improved metabolic control, a significant decrease of urinary excretion and plasma levels of catecholamines was observed. The results confirm that there is an increased rate of catecholamine release in poorly controlled diabeties and suggest a close correlation between sympathetic activity and metabolic derangement in diabetes.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 499999     DOI: 10.1055/s-0028-1092768

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  6 in total

Review 1.  Diabetes mellitus and burns. Part I-basic science and implications for management.

Authors:  Ioannis Goutos; Rebecca Spenser Nicholas; Atisha A Pandya; Sudip J Ghosh
Journal:  Int J Burns Trauma       Date:  2015-03-20

2.  The influence of beta-adrenoceptor blocking drugs with and without intrinsic sympathomimetic activity on the hormonal responses to hypo- and hyperglycaemia.

Authors:  K J Schlüter; W H Aellig; K G Petersen; H C Rieband; A Wehrli; L Kerp
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

3.  Urinary excretion and plasma levels of norepinephrine and epinephrine during diabetic ketoacidosis.

Authors:  G Bolli; P Compagnucci; M G Cartechini; P De Feo; F Santeusanio; A Puxeddu; P Brunetti
Journal:  Acta Diabetol Lat       Date:  1979 Apr-Jun

Review 4.  Epalrestat. A review of its pharmacology, and therapeutic potential in late-onset complications of diabetes mellitus.

Authors:  J W Steele; D Faulds; K L Goa
Journal:  Drugs Aging       Date:  1993 Nov-Dec       Impact factor: 3.923

5.  Impact of diabetes mellitus on bladder uroepithelial cells.

Authors:  Ann T Hanna-Mitchell; Giovanni W Ruiz; Firouz Daneshgari; Guiming Liu; Gerard Apodaca; Lori A Birder
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2012-11-21       Impact factor: 3.619

6.  Lack of glucagon response in glucose counter-regulation in type 1 (insulin-dependent) diabetics: absence of recovery after prolonged optimal insulin therapy.

Authors:  G Bolli; G Calabrese; P De Feo; P Compagnucci; G Zega; G Angeletti; M G Cartechini; F Santeusanio; P Brunetti
Journal:  Diabetologia       Date:  1982-02       Impact factor: 10.122

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.